Oculis to present phase 3 DIAMOND program updates at Innovate Retina and Eyecelerator 2024

(Image credit: AdobeStock/New Africa)

Oculis announced updates for its DIAMOND phase 3 trial of OCS-01, an OPTIREACH formulation of high-concentration dexamethasone eye drop, for diabetic macular edema (DME) will be presented by David Eichenbaum, MD at Innovate Retina. Additionally, Riad Sherif, MD, CEO of Oculis will present at Eyecelerator

The presentations will highlight results from stage 1 of the DIAMOND program at week 12, and the design of stage 2 to assess the efficacy and safety of OCS-01 eye drops for the treatment of DME at Week 52 will also be highlighted.¹ Sherif’s presentation at Eyecelerator will also touch upon topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic neuritis (AON)

Both the DIAMOND-1 and DIAMOND-2 phase 3 trials are ongoing, double-masked, randomized, multi-center trials evaluating the efficacy and safety of OCS-01 eye drops in patients with DME. Oculis aims to enroll 350 patients in each of these trials where they will be treated 1:1 to receive OCS-01 or vehicle 6 times daily for the 6-week induction phase and then three times daily through week 52 for the maintenance phase. The primary endpoint of both trials is change in best corrected visual acuity early treatment diabetic retinopathy study (BCVA ETDRS) letter score at Week 52.¹

According to Oculis, OSC-01, a non-invasive eye drop targeting the retina to treat DME, was developed to transform the current treatment paradigm in DME as a non-invasive topical treatment option.¹

As previously mentioned, Sherif’s presentation will also touch upon the Phase 2 ACUITY trial, an ongoing randomized, double-blind, multi-center, two-arm, placebo-controlled study evaluating the safety and tolerability of once daily OCS-05 intravenous infusion in patients with AON.

OCS-05 is a serum-glucose corticoid kinase-2 (SGK-2) activator where, according to Oculis, the mechanism of action could potentially protect nerve axons in conditions such as AON, to ultimately prevent vision loss.¹

Additional information on the presentations can be found below:

Eyecelerator 2024

• Session: Retina Showcase
• Presenter: Riad Sherif, MD, Chief Executive Officer, Oculis
• Presentation date and time: October 17, 2024 at 2:06 pm CT
• Location: McCormik Place, Chicago, IL

Innovate Retina

• Presentation title: OCS-01: novel topical approach for macular edema
• Session: New Routes and New Molecules
• Presenter: David Eichenbaum, MD
• Presentation date and time: October 17, 2024 at 5:31 pm CT
• Location: InterContinental Chicago Magnificent Mile, Chicago, IL

References:

1. Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024. Press Release; October 15, 2024. Accessed October 15, 2024. https://www.biospace.com/press-releases/oculis-diamond-phase-3-program-in-diabetic-macular-edema-to-be-presented-at-innovate-retina-and-eyecelerator-2024